Mallinckrodt Pharmaceuticals
387 articles about Mallinckrodt Pharmaceuticals
-
Mallinckrodt Pharmaceuticals Receives FDA Approval For XARTEMIS XR (Oxycodone Hydrochloride And Acetaminophen) Extended-Release Tablets (CII)
3/12/2014
-
Mallinckrodt Pharmaceuticals To Present At Barclays Global Healthcare Conference
2/28/2014
-
Mallinckrodt Pharmaceuticals Receives Patent From U.S. Patent And Trademark Office
2/25/2014
-
Mallinckrodt Pharmaceuticals Adds Pain Drug With $1.3 Billion Cash Cadence Pharmaceuticals, Inc. Buyout
2/11/2014
-
Nuvo Research Inc. Announces The U.S. Commercial Launch Of PENNSAID® 2% By Mallinckrodt Pharmaceuticals
2/10/2014
-
Mallinckrodt Pharmaceuticals’ New Drug Available To Patients
2/10/2014
-
Mallinckrodt Pharmaceuticals To Present At Leerink Swann and Company Global Healthcare Conference
2/5/2014
-
Mallinckrodt Pharmaceuticals Rises As New Drug App Is Approved By The FDA
1/17/2014
-
Mallinckrodt Pharmaceuticals And Medtronic, Inc. Announce Clinical And Commercial Collaboration
1/13/2014
-
Zogenix, Inc. And Mallinckrodt Pharmaceuticals Agree To End Co-Promotion For SUMAVEL® Dosepro® Effective January 31, 2014
1/9/2014
-
Mallinckrodt Pharmaceuticals To Report First Quarter Results On Thursday, February 6, 2014
1/7/2014
-
Mallinckrodt Pharmaceuticals Announces Completion Of MNK-155 Clinical Trials
12/12/2013
-
FDA Extends Review of Mallinckrodt Pharmaceuticals' New Drug Application For XARTEMIS XR (Oxycodone Hydrochloride And Acetaminophen) Extended-Release Tablets (CII)
11/25/2013
-
China Resources To Distribute Imaging Agent For Mallinckrodt Pharmaceuticals
11/19/2013
-
Mallinckrodt Pharmaceuticals to Hold Investor Briefing in New York
11/8/2013
-
Mallinckrodt Pharmaceuticals to Hold Investor Briefing in New York
11/8/2013
-
Mallinckrodt Pharmaceuticals Announces Executive Appointments
10/24/2013
-
Mallinckrodt Pharmaceuticals Provides Financial Outlook for Fiscal Year 2014
10/16/2013
-
Mallinckrodt Pharmaceuticals's Extended-Release Pain Drug Meets Main Goal in Phase 3 Trial
9/6/2013
-
Mallinckrodt Pharmaceuticals Reports Human Abuse Liability (HAL) Data for MNK-795, an Extended-Release Oxycodone/Acetaminophen Combination
9/4/2013